Schroder Investment Management Group raised its stake in shares of Davita Inc (NYSE:DVA) by 102.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 265,663 shares of the company’s stock after buying an additional 134,558 shares during the quarter. Schroder Investment Management Group owned about 0.16% of Davita worth $18,636,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Oppenheimer Asset Management Inc. purchased a new position in Davita during the second quarter valued at $3,421,000. OppenheimerFunds Inc. raised its stake in shares of Davita by 58.7% in the second quarter. OppenheimerFunds Inc. now owns 4,066,317 shares of the company’s stock worth $282,365,000 after purchasing an additional 1,504,347 shares during the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of Davita in the second quarter worth $1,627,000. Alps Advisors Inc. raised its stake in shares of Davita by 11.1% in the second quarter. Alps Advisors Inc. now owns 10,781 shares of the company’s stock worth $749,000 after purchasing an additional 1,080 shares during the last quarter. Finally, Hikari Tsushin Inc. raised its stake in shares of Davita by 10.5% in the second quarter. Hikari Tsushin Inc. now owns 74,410 shares of the company’s stock worth $5,624,000 after purchasing an additional 7,050 shares during the last quarter. Institutional investors and hedge funds own 87.71% of the company’s stock.
DVA stock opened at $70.14 on Tuesday. Davita Inc has a 1-year low of $52.51 and a 1-year high of $80.71. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.90 and a quick ratio of 1.88. The firm has a market capitalization of $11.67 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.04 and a beta of 1.11.
Several research firms have recently weighed in on DVA. Zacks Investment Research upgraded Davita from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. William Blair restated a “buy” rating on shares of Davita in a research note on Wednesday, June 6th. Finally, JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Davita currently has an average rating of “Buy” and an average target price of $82.13.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Risk Tolerance
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.